$44.12
0.210.48%
Last update: Nov 11, 1:34 PM
Rigel Pharmaceuticals Inc
RIGLNASDAQ
Rigel Pharmaceuticals rose 15.7% from $37.95 to $43.91, ahead of the S&P 500's +9.8%. Its worst day was Nov 6 (−13.3%), and its low came Mar 18 at $25.44.
Nov 11, 2025 – Nov 10, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Rigel Pharmaceuticals shares fell 9.8%, while the S&P 500 rose 0.4%.
−9.8% · S&P 500 +0.4%
R289 continues to be generally well tolerated and at doses of ≥500 mg QD preliminary efficacy was observed in elderly, heavily pre-treated lower-risk MDS patientsRBC-TI was achieved by 33% (6/18) of evaluable transfusion
Story events cover the past 12 months · Times ET
−11.3% · S&P 500 −0.3%
Rigel Pharmaceuticals shares rose 8.7%, while the S&P 500 fell 0.3%.
+8.7% · S&P 500 −0.3%
EPS of $1.12 missed the $1.25 estimate on $69.8M revenue (est. $69.1M); FY revenue guidance of $275.0M–$290.0M against the $281.8M consensus.
−10.3% · S&P 500 +0.7%
Rigel Pharmaceuticals closed at its lowest level of the year, 33.0% below where the year started.
−3.6% · S&P 500 −1.4%
EPS of $0.44 missed the $0.85 estimate on $58.8M revenue (est. $62.0M); FY revenue guidance of $275.0M–$290.0M against the $284.3M consensus.
−5.1% · S&P 500 +1.4%
Rigel Pharmaceuticals shares fell 9.1%, while the S&P 500 fell 1.2%.
−9.1% · S&P 500 −1.2%
EPS of $0.88 beat the $0.17 estimate on $78.7M revenue (est. $58.6M); FY revenue guidance of $285.0M–$295.0M against the $277.4M consensus.
+4.6% · S&P 500 −0.2%
Rigel Pharmaceuticals closed at its highest level of the year, 35.6% above where the year started.
+1.4% · S&P 500 −0.4%
EPS of $0.65 missed the $0.94 estimate on $80.9M revenue (est. $79.7M); FY revenue guidance of $290.0M–$295.0M against the $304.3M consensus.
−13.3%, the year's worst day · S&P 500 +0.3%
Where it ended: a close of $43.91 on Nov 10, 2026. Up next: Q4 2026 earnings on Mar 2, 2027 (EPS est. $1.10, revenue est. $88.0M).
Nothing in the past 12 months.
All RIGL dividend historyReplay the year: the line draws itself and stops at each of the 10 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for RIGL and SPY from Benzinga historical bars. Not investment advice.
